| Ms Patricia Livingston, APRN | |
|
425 Pearl St, Burlington, VT 05401-3308 | |
| (802) 656-3350 | |
| Not Available |
| Full Name | Ms Patricia Livingston |
|---|---|
| Gender | Female |
| Speciality | Registered Nurse - Women's Health Care, Ambulatory |
| Location | 425 Pearl St, Burlington, Vermont |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043314537 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 163WW0101X | Registered Nurse - Women's Health Care, Ambulatory | 1010012288 (Vermont) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Ms Patricia Livingston, APRN 425 Pearl St, Burlington, VT 05401-3308 Ph: (802) 656-3350 | Ms Patricia Livingston, APRN 425 Pearl St, Burlington, VT 05401-3308 Ph: (802) 656-3350 |
News Archive
The cool, crisp air will soon be filled with the tantalizing scent of fried candy bars, funnel cakes and candy apples. Local and state fairs may offer thrilling rides and fun games, but perhaps the biggest attraction is the food.
PBS NewsHour's blog "The Rundown" examines a "report from the U.N.'s Every Woman, Every Child Innovation Working Group, out in the Lancet Monday, which looks at some of the promising and innovative projects" aimed at improving maternal and child health
The International Myeloma Foundation (IMF)—supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians—today said presentations at the annual meeting of the American Society of Hematology (ASH) will cover all stages of multiple myeloma, a major milestone in treating this and related cancers.
ZymoGenetics, Inc. today announced the initiation of the second part of a Phase 2 clinical trial with PEG-Interferon lambda (IL-29) and ribavirin in treatment-naïve patients with chronic hepatitis C virus (HCV) infection. ZymoGenetics is developing the investigational compound PEG-Interferon lambda in collaboration with Bristol-Myers Squibb Company.
Oncolytics Biotech Inc. has announced that it has started patient enrolment in a Phase 2 clinical trial using intravenous administration of Reolysin in combination with paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC) with K-RAS or EGFR-activated tumours.
› Verified 1 days ago
Brittney Alyssa Accavallo, RN Registered Nurse Medicare: Medicare Enrolled Practice Location: 111 Colchester Ave, Burlington, VT 05401 Phone: 802-847-0000 | |
Rebecca O Beaudoin, R.N., C.D.E Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 111 Colchester Ave, Csc, Burlington, VT 05401 Phone: 802-847-6200 Fax: 802-847-5364 | |
Nicole Marie Cloutier, Registered Nurse Medicare: Medicare Enrolled Practice Location: 111 Colchester Ave, Burlington, VT 05401 Phone: 802-847-2370 | |
Rachel Ivancie, CNM, APRN, WHNP-BC Registered Nurse Medicare: Accepting Medicare Assignments Practice Location: 617 Riverside Ave, Burlington, VT 05401 Phone: 802-864-6309 | |
Kelsey Rumley, DNP, FNP-C Registered Nurse Medicare: Medicare Enrolled Practice Location: 1205 North Ave, Burlington, VT 05408 Phone: 802-863-1313 | |
Ms. Dori E. Weigand, MSN, APRN Registered Nurse Medicare: Accepting Medicare Assignments Practice Location: 168 Battery St, Burlington, VT 05401 Phone: 802-735-6895 Fax: 802-860-2399 |